Astellas Launches Hostile Bid To Acquire OSI Of U.S. For $3.5 Billion
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma says it intends to acquire U.S.-based OSI Pharmaceuticals for $3.5 billion, with the offer closing March 31